Search filters
Filters
Clear All

Phase

  • 1
  • 2
  • 1
  • 2
  • 6
  • 1
  • 3
  • 3

Found 6 Endometrial Cancer trials

A listing of Endometrial Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018 (REGN5668)

18-100 years
Female
Phase 1/2
This study is divided into 2 parts (Escalation and Expansion).  Your study doctor or study staff will also let you know you in what part of the study you will participate.The purpose of Part 1 (Escalation) of the study is to find the highest, safe dose of the study drug(s), …
Learn More

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (NRG-GY031)

18-99 years
Female
Phase 1
To determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for combination of ATR inhibitor (M1774) and BET inhibitor (ZEN003694) in women with recurrent clear cell, endometrioid, and platinum resistant high grade serous ovarian carcinoma (HGSOC) and clear cell and endometrioid endometrial carcinoma irrespective of ARID1A status.The target …
Learn More

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (IMGN151)

18-99 years
All genders
To assess safety and tolerability, including dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), or maximum administered dose (MAD; if no MTD is defined) of IMGN151 when administered intravenously To determine recommended Phase 2 dose (RP2D) for IMGN151 To characterize the pharmacokinetics (PK) and immunogenicity of IMGN151 -To assess ORR for …
Learn More

EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib alone in Patients with recurrent or persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial

99 years and younger
All genders
Cohort 1:Compare progression free survival of combination of olaparib and selumetinib to selumetinib alone in patients with RAS mutant ovarian cancer. Cohort 2:Compare progression free survival of combination of olaparib and selumetinib to selumetinib alone in patients with RAS mutant endometrial cancer.
Learn More

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies (Xencor)

18 years and older
All genders
Phase 2
The purpose of the study is to assess whether an investigational drug, called XmAb20717, has any effects on certain types of cancers and if it is safe and well tolerated.
Learn More

A Study of CPI-0209 in Patients with Advanced Solid Tumors and Lymphomas (CPI 0209)

18-99 years
Female
Phase 1/2
First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209 is a small molecule inhibitor of EZH2.
Learn More